Investigate the tumor microenvironment with high-plex imaging
Explore Dr. David Rimm’s strategy for biomarker discovery
Find out why Dr. Rimm’s work suggests that a subset of cells that have lost beta-catenin expression may be associated with non-response. In this seminar recording from USCAP 2020, Dr. Rimm explains how you can benefit from exploratory analysis using AI-powered phenotyping.
In this video, Dr. Rimm will discuss:
- How his lab used tSNE plots to show differences between responders and non-responders to trastuzumab
- Methods of measurement like co-localization, compartmentalization, and measurement vs segmentation and counting
Learn how his group used Visiopharm AI-based software to help them get meaningful results from next-gen imaging technologies like Fluidigms IMC.
Meet your speaker
David Rimm, MD, PH.D.
Professor of Pathology and Medicine (Oncology)
Director of Yale Pathology Tissue Services.
Yale School of Medicine
David has authored over 400 peer-reviewed papers and holds eight patents. His research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative methods, including Visiopharm´s phenotyping module.
His projects relate to predicting response to both targeted and immune- therapy in cancer and standardization of those assays for CLIA labs.
Source: Visiopharm
